Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ENZC is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases.
That was sent to SAGA shareholders.
$105 billion Potential Profit from Technology
Projected Earnings from the BioClonetics’ passive immunotherapy have been calculated by an independent national consulting firm. This analysis examines the expected potential profits from 2 perspectives: (1) considering sales only to North America and Western Europe and (2) considering sales to the major Markets including North America, Western and Central Europe, Eastern Europe and Central Asia, South and Southeast Asia and Latin America. The potential earnings and underlying assumptions for application of our passive immunotherapy to major Markets are set forth here:
A most appropriate market for the Company’s therapy includes the regions referred to as the “Major Markets”, including North American, Western and Central Europe, Eastern Europe and Central Asia, South and Southeast Asia and Latin America wherein there are 10.6 million HIV positive individuals. Assuming a penetration rate of 1% rising to a maximum 15% over a five-year period, profit from making treatment available to these 10.6 million HIV positive individuals in the 7 major world markets would be $105 billion in the first 11 years.
httpNs://viocloneticz.com/pofit-patential.rs
Objective people understand this.
Emotional people cry and say Zach is lying because the price didn't do what they wanted.
Can I have the key?
We Can. We Will. End of Story.
#ENZCSTRONG
A B C D E
mAbs will save humanity
And so it will be
#ENZCSTRONG
As long as those entities have less than 141,521,797 shares they wouldn't need the 13f - correct me if I'm wrong.
Don't let anyone distract you from the fact that the Toronto Bulls made a game winning home run from the 50 yard line with only 20 seconds to go in the third half of the super playoffs.
And Enzolyitcs science will win!
KLIC gon kill that HIV bruh
Then maybe you can be cured of your haids
:)
Go Timberdogs!
The glass can never be empty - it's always full! Literally cannot be empty unless it's in a vacuum where there is no other matter.
HBD!
Great find - and it comes from the world's largest market research store:
https://www.researchandmarkets.com/about-us
Quite suitable for Samsung & Enzolytics to be included in their data.
It's amazing how far behind the federal government is with their antibody research if they are only claiming two out of the several that Enzolytics had claimed over a year before the federal government published anything.
It's also interesting how the Federal Register is offering this patent application up for licensing even though it isn't even publicly available to search yet.
"Intellectual Property: HHS Reference No. E–047–2022–0–EIR–00 U.S. Patent
Application No. 63/308,898, filed on February 10, 2022."
I guess you can say that Enzolytics is lightyears ahead!
For those naysayers - the federal government is claiming that their two antibodies have "Potential Commercial Applications" ... the same antibodies they are claiming in their patent filed AFTER Enzolytics - which reference the same sites as our patents. We are PRIOR ART for their application.
PDF Link for anyone wanting to read more: https://www.govinfo.gov/content/pkg/FR-2022-06-10/pdf/2022-12485.pdf
Credit to ENZC_crd
We Can. We Will. End of Story.
#ENZCSTRONG
Agree on all fronts.
Also - although Harry has had a certain past... I wouldn't discount his knowledge, experience, abilities. He has secured several patents on emerging technology. There is just a cloud following him.
If society valued knowledge and progress above profits, none of these things we see today would have gotten in his way.
The ego is something we need a cure for IMO.
We can. We will. End of story.
#ENZCSTRONG
Exactly - right now the tide is going out, stranding some sea creatures. Soon it will rise and the wave will crest.
We Can. We Will. End of Story.
Some will be surfing the tsunami while some will get washed away.
Few.
#ENZCSTRONG
And this might just be the teaser for their new Plant 4 starting operations this month:
"Touting its manufacturing capability, John Rim, CEO of Samsung Biologics, said the planned partial operation will add fresh new capacity of 60,000 liters in October, keep the company unparalled in the market."
https://www.koreaherald.com/view.php?ud=20220113000773
Bingo
20-fold lower toxicity than . . . Tamiflu®
"The results show that while the tested therapeutics had comparable effectiveness, ITV-1/IPF had a 20-fold lower toxicity than the widely used anti-influenza medicine Tamiflu®"
Because Android > Apple & OTC Markets is the best place to get news right now.
Enzolytics Reports Successful Completion of an MTD Tolerability Study of Its ITV-1 anti-HIV Therapeutic Leading to the Start of a 28-day GLP Toxicology Study
https://www.otcmarkets.com/stock/ENZC/news/Enzolytics-Reports-Successful-Completion-of-an-MTD-Tolerability-Study-of-Its-ITV-1-anti-HIV-Therapeutic-Leading-to-the-S?id=374896
Entities with whom the Company is working include other Biotech
- Technology and processes for accelerating the production of monoclonal antibodies that target critical virus
sites identified by the Company using its A.I. platform. The Company has identified critical conserved target
sites on 20 viruses, including human and animal viruses, and is engaging with biotech companies having
expertise in accelerating the production of such antibodies.
- Related, synergistic or complimentary therapeutics and business structure for the purpose of potential
combination with other biotech entities.
- Expertise in providing specialized peptides having precise amino acid sequences corresponding to the precise
target sites on both the Coronavirus and HIV viruses which are then used in the Company’s Texas lab against
which mAbs are being produced. This strategy accelerates the production of the mAbs for further development.
- Specialized cell sorting technology that is complementary to the process used in the Company’s lab to
accelerate production of mAbs for advancing production.
- Expertise in hybridoma production techniques for producing mAbs using hybridoma methodologies
complementary to the process used in the Company's lab.
- Animal trials centers, both in the U.S. and abroad, for the preparation of animal trials.
- Promotional entities with specialized expertise in targeting large funding sources for the purpose of raising the
substantial funds needed for the production of the recombinant mAbs necessary for future trials and for
conducting animal trials.
How bout dem fax
https://www.otcmarkets.com/otcapi/company/financial-report/346487/content
See no proof - therefore fact.
Oh yea prove it with verifiable links and a dissertation.
This is a fact.
I really like all that progress you posted - absolutely amazing company progress.
The Law! Great to see you around these parts again.
I certainly will never get tired of hearing about monoclonal antibodies. Especially next-generation monoclonal antibodies including circulating IgA antibodies for which there is a significant role for mucosal immunity in viruses such as COVID-19.
Intellectual Property (I.P). Portfolio
A.I. Driven Diagnostics
Enzolytics is developing Artificial Intelligence for use in in-vitro diagnostic tests that diagnose viral diseases based on the presence of the conserved sites that remain unaffected by mutations. Enzolytics has identified conserved targets for many infectious diseases for humans and animals. The Company has identified conserved targets for SARS-CoV-2, HIV, rabies, influenza A, influenza B, HTLV1, Herpes, Smallpox, Ebola, Equine Infectious Anemia, Feline leukemia virus, Feline immunodeficiency virus, and Koala Retrovirus. More information has been published by the Company in its Press Release of February 21, 2022. https://www.accesswire.com/viewarticle.aspx?id=689605
Documented studies show better clinical outcomes and delayed progression of diseases if patients have the antibodies to the conserved targets. Enzolytics is working on prognostic tests utilizing A.I. to predict the immune response before receiving viral therapy. This will allow physicians to understand if a patient will respond to a particular antiviral treatment. More information on this technology has been presented by Dr. Chandra, the Company's COO, published in The Yuan on April 4, 2022. https://www.the-yuan.com/269/AI-Driven-Diagnostics-Transform-Healthcare.html
https://www.otcmarkets.com/stock/ENZC/news/CORRECTION-Enzolytics-Inc-Reports-Progress-and-Future-Plans?id=353685
Enzolytics Artificial Intelligence Platform
#ENZCSTRONG WE CAN. WE WILL. END OF STORY.
Great post Timing - as always.
It's good to keep all of the updates fresh in your mind as they are all related and part of the plan. The progress they've had over the past several months is the result of a professional team that has a plan in place. A plan that is being executed. A plan that will result in a better future - for all.
Enzolytics Announces the Appointment of Steve Sharabura as President of its Wholly Owned Subsidiary RobustoMed, Inc (A/K/A ENZO SUB)
Enzolytics Inc. Reports Test Results of its Patented ITV-1 Conducted at the National Centre of Infectious and Parasitic Diseases